Clinical trials: doxorubicin hydrochloride
Lymphoma
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002571
- Testing
- bleomycin sulfate, filgrastim, cyclophosphamide
- Where
- 85 sites in United States
- Volunteers
- 52 people
- Sponsor
- SWOG Cancer Research Network
Estrogen Receptor Negative, HER2/Neu Negative
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
This phase I clinical trial studies the side effects and the best dose of dinaciclib when given together with epirubicin hydrochloride (epirubicin) in patients with metastatic (cancer that has spread to other parts of the body)…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01624441
- Testing
- Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Solid Tumour
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
This is a phase 1b open-label study evaluating the preliminary safety and maximum tolerated dose of a new formulation of INNO-206 administered at doses of 230 mg/m2, 350 mg/m2 and 450 mg/m2 (165, 260, 325 mg/m2 doxorubicin…
- Trial name
- NCT01337505
- Testing
- INNO-206
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- ImmunityBio, Inc.
Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma.
- Trial name
- NCT00669877
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
Rhabdomyosarcoma, Neuroblastoma
HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
The purpose of this study is to determine whether Doxil (liposomal doxorubicin) given prior to MR-HIFU Hyperthermia is safe for the treatment of pediatric and young adult patients with recurrent and refractory solid tumors.
- Conditions
- Rhabdomyosarcoma, Neuroblastoma, Sarcoma, Sarcoma, Ewing
- Trial name
- NCT02557854
- Testing
- Doxorubicin HCl liposomal injection, Philips Sonalleve MR-HIFU Hyperthermia
- Where
- United States
- Sponsor
- Theodore Laetsch
Breast Cancer
Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer
Intensive sequential chemotherapy with Adriamycin Taxol and Cytoxan in the treatment of locally advanced breast cancer
- Trial name
- NCT00538395
- Testing
- Adriamycin, Taxol and Cytoxan
- Volunteers
- 100 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Breast Cancer
MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study
Many patients with breastcancer in the past, were treated with TAC. These last years, there is more and more focus on the effects of chemotherapy, particularly in children treated with this.
- Trial name
- TOXTAC (NCT01246856)
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Radboud University Medical Center
Ovarian Epithelial Cancer
Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the…
- Trial name
- CLIO (NCT02822157)
- Testing
- Olaparib, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
- Where
- Belgium
- Volunteers
- 160 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective following surgery for breast…
- Trial name
- NCT00003012
- Testing
- CMF regimen, cyclophosphamide, epirubicin hydrochloride
- Where
- 10 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Scottish Cancer Therapy Network
Thyroid Neoplasms, Carcinoma
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this.
- Conditions
- Thyroid Neoplasms, Carcinoma, Thyroid Cancer, Metastatic Cancer
- Trial name
- NCT00804830
- Testing
- Bevacizumab
- Where
- 3 sites in Sweden
- Volunteers
- 15 people
- Sponsor
- Region Skane
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
This retrospective multicenter study aims to evaluate whether radiographic microvascular invasion (MVI) status can predict treatment response in patients with intermediate-stage hepatocellular carcinoma (HCC) receiving…
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI), Tyrosine Kinase Inhibitors
- Trial name
- NCT07449065
- Testing
- TKI, TACE
- Where
- China
- Volunteers
- 324 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Mantle Cell Lymphoma
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
The purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody followed by CHOP and to see what effects it has on patients with previously untreated mantel cell lymphoma.
- Trial name
- NCT00022945
- Testing
- Iodine-131 Anti-B1 Antibody, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
- Where
- 3 sites in United States
- Sponsor
- Corixa Corporation
Plasma Cell Leukemia, Multiple Myeloma
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Bortezomib/Liposomal doxorubicin (V-DD) is preferred to bortezomib single agent in salvage therapy for Multiple Myeloma (MM). The present study is designed to assessment the efficacy and safety study of Bortezomib in combination…
- Trial name
- Bortezomib (NCT01328236)
- Testing
- Bortezomib, Liposome doxorubicin, Dexamethasone
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Clinical Service, China
Leukemia-Lymphoma, Adult T-Cell
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
The rationale of the current study is to explore the use of combination chemotherapy together with antiretroviral agents in order to determine the efficacy and toxicity of this approach, while also examining markers of virus…
- Trial name
- ATLL (NCT01000285)
- Testing
- Bortezomib, Etoposide, Vincristine
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Primary Gastric Diffuse-Large B-Cell Lymphoma
Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The optimal treatment of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) has not yet been defined. In most circumstances, a stomach-conserving approach is favored, but the role of radiotherapy is still a matter of…
- Trial name
- NCT00204659
- Testing
- Rituximab + CHOP chemotherapy
- Where
- 5 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Tuebingen
Non Hodgkin Lymphoma, Follicular Lymphoma
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
This is a prospective multicenter phase II pilot trial designed with the purpose of dose finding to evaluate the efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated…
- Trial name
- REAL07 (NCT00907348)
- Testing
- LR-CHOP21
- Where
- 18 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and best dose of ruxolitinib phosphate and how well it works compared to dasatinib when given with chemotherapy in treating patients with Philadelphia chromosome-like acute…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Ph-Like Acute Lymphoblastic Leukemia
- Trial name
- NCT02420717
- Testing
- Cyclophosphamide, Cytarabine, Dasatinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B Cell Lymphoma
Treatment of Diffuse Large B Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma.
- Trial name
- NCT01949818
- Testing
- Yangzhengxiaoji capsule combined with CHOP regimen, CHOP regimen
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Mingzhi Zhang
Soft Tissue Sarcoma, Neoplasms, Connective and Soft Tissue
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the first-line treatment of advanced soft tissue sarcoma
- Conditions
- Soft Tissue Sarcoma, Neoplasms, Connective and Soft Tissue, Sarcoma Metastatic, Sarcoma,Soft Tissue
- Trial name
- NCT04910126
- Testing
- Camrelizumab, Adriamycin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Glioblastoma
Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas
Anti-EGFR-immunoliposomes loaded with doxorubicin (C225-ILs-dox) are given intravenously in patients with relapsed or refractory high-grade gliomas.
- Trial name
- GBM-LIPO (NCT03603379)
- Testing
- C225-ILs-dox
- Where
- 2 sites in Switzerland
- Volunteers
- 9 people
- Sponsor
- University Hospital, Basel, Switzerland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.